Differential features of pro-inflammatory eicosanoids in exhaled breath condensate and sputum from asthmatics
Sunday, March 4, 2018
South Hall A2 (Convention Center)
Yoshitaka Uchida, MD, Tomoyuki Soma, MD PhD, Takehito Kobayashi, MD, PhD, Kazuyuki Nakagome, MD PhD, Makoto Nagata, MD PhD

Eicosanoids are involved and may play roles in airway inflammation of asthma. Levels of eicosanoids in exhaled breath condensate (EBC) and sputum vary in chronic asthma and their association with clinical indicators remains insufficiently evaluated. Here, we measured pro-inflammatory eicosanoids in EBC and sputum to comprehensively assess their levels among the different severities of asthma and healthy volunteers and their association between in EBC and sputum and with pulmonary function.


EBC and sputum were obtained from 52 adult stable asthmatics and 11 healthy volunteers. Pulmonary function test was conducted in all subjects. The concentrationa of cysteinyl leukotrienes (CysLTs), leukotriene B4 (LTB4), prostaglandin D2 (PGD2) and thromboxane B2 (TXB2) were measured using ELISA.


CysLTs and PGD2 levels in EBC and sputum in asthmatics were significantly higher than healthy volunteers (EBC: p < 0.01 and p < 0.05, sputum: p < 0.01 and p < 0.05, respectively). In EBC, CysLTs, PGD2 and LTB4 levels in severe asthma were significantly higher than other asthma severities. CysLTs and PGD2 levels in EBC were not correlated with those levels in sputum, respectively. Increases in PGD2 in EBC were solely correlated with decreases in pulmonary function in asthma (r = -0.24, p = 0.03).


In the airway of severe asthma, pro-inflammatory eicosanoids seem to be persistently increased regardless of treatment. EBC eicosanoids appear more indicative of asthma severity than sputum. Especially, PGD2 in EBC is likely involved in deterioration of pulmonary function under guideline treatment of asthma.